Compare ACM Research Inc (ACMR) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACM Research Inc vs DexCom, Inc. — how do they compare? ACM Research Inc trades at $83.46 (market cap $5.57B), while DexCom, Inc. trades at $89.03 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 6.1× ACM Research Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | DXCM | |
|---|---|---|
Market Cap | $5.57B | $33.79B |
Sector | Technology | Health |
52-Week High | $126.89 | $89.53 |
52-Week Low | $24.93 | $54.84 |
Enterprise Value | $4.48B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $83.03, up 4.56% in the last session, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.61 versus $0.42 expected, and revenue grew 36% year-over-year to $292.9 million. The company raised its 2026 revenue guidance amid strong order growth of 105% in the first half, driven by new products like the Ultra C Tahoe wet processing platform expansion announced on August 7, 2026.
Outlook is positive with 80% analyst buy ratings and a consensus price target of $127.50, implying 54% upside. Risks include high valuation with a P/E of 37.7 and reliance on semiconductor cycle demand. Net cash flow improved to $538 million in 2026 from $355 million in 2025, supporting growth initiatives.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
